Core Viewpoint - Shanghai Titan Technology Co., Ltd. plans to acquire 100% equity of Apollo Scientific Ltd. from Central Glass Japan for £5,756,429, aiming to enhance its international presence and core competitiveness [1][2][3]. Group 1: Investment Overview - The company intends to use its own or self-raised funds for the acquisition, which is not classified as a related party transaction or a major asset restructuring [1][4]. - The transaction is part of the company's strategic plan to expand overseas sales channels and accelerate internationalization [2][3]. Group 2: Transaction Details - The acquisition will result in Apollo Scientific Ltd. being included in the company's consolidated financial statements as a subsidiary [3]. - The transaction is subject to approval from relevant national and local authorities, and the company has authorized its management to handle the necessary procedures [4][5]. Group 3: Target Company Information - Apollo Scientific Ltd. is a private limited company registered in England, primarily engaged in the distribution and customized services of chemical products [6][7]. - The financial performance of Apollo Scientific Ltd. shows a revenue of £8.71 million in 2024 and a net loss of £0.55 million, with total assets of £11.55 million and total liabilities of £0.96 million [7][8]. Group 4: Strategic Benefits - The acquisition is expected to enhance the company's sales and warehousing systems, facilitating faster responses to overseas customer demands and expanding its global reach [3][8]. - The integration of Apollo Scientific Ltd. is anticipated to improve procurement channels and optimize costs, thereby enhancing profitability [3][8]. Group 5: Due Diligence and Valuation - The company has engaged professional institutions for legal and financial due diligence, ensuring compliance and risk assessment related to the transaction [8][9]. - The purchase price was determined based on the target company's net assets and potential business synergies, amounting to £5,756,429 (approximately ¥55.85 million) [8][9].

证券代码：688133 证券简称：泰坦科技 公告编号：2025-029 上海泰坦科技股份有限公司 关于拟收购境外公司股权并签署股权收购协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 对外投资概况：上海泰坦科技股份有限公司（以下简称"公司"）拟使 用自有或自筹资金 5,756,429 英镑（以 2025 年 7 月 23 日汇率折合人民币约 5,585 万元）收购中央硝子株式会社（即 Central Glass Co., Ltd，东京证券交 易所上市公司，股票代码 4044，以下简称"Central Glass 日本"）持有的 Apollo Scientific Ltd.（英格兰注册的私人股份有限公司，以下简称"标的公 司"或"ASL"） 100%的股权。（以下简称"本次交易"） 本次交易涉及境外投资，相关股权和资产的交割须符合所在地区法律规定和 监管部门要求。 其它需要提醒投资者重点关注的风险事项： 由于交易架构复杂，交易双方分别为中国和日本证券交易所上市的企业，交 易标的涉及全球多地的法律、财 ...

Core Viewpoint - Titan Technology plans to acquire 100% of Apollo Scientific Ltd. (ASL) from Central Glass Japan for £5.7564 million (approximately 55.85 million RMB) to enhance its international presence and competitiveness in the chemical distribution sector [1] Group 1: Acquisition Details - The acquisition will make ASL a subsidiary of Titan Technology, included in its consolidated financial statements [1] - ASL specializes in the supply of chemicals and related products, focusing on distribution and customized services [1] Group 2: Strategic Objectives - The transaction aims to expand overseas sales channels and improve the company's international layout [1] - The acquisition is part of Titan Technology's strategy to accelerate its internationalization process and enhance core competitiveness [1] Group 3: Regulatory Requirements - The transaction is subject to approval and filing with relevant national and local authorities [1]

中信证券股份有限公司 关于上海泰坦科技股份有限公司 使用部分闲置募集资金暂时补充流动资金之核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为上海 泰坦科技股份有限公司（以下简称"泰坦科技"或"公司"）2021 年度向特定 对象发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司募集资金监管规则》等有关法律法规和规范性文 件的要求，对泰坦科技拟使用部分闲置的 2021 年度向特定对象发行 A 股股票募 集资金暂时补充流动资金的事项进行了认真、审慎的核查，发表如下意见： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海泰坦科技股份有限公司向特定 对象发行股票注册的批复》（证监许可〔2022〕871 号），上海泰坦科技股份有 限公司向特定对象发行 A 股股票 7,624,896 股，发行价格为人民币 131.61 元/股， 本次发行的募集资金总额为人民币 1,003,512,562.56 元，扣除相关发行费用人民 币 18,328,561.10 元，募集资金净额为 ...

重要内容提示： 证券代码：688133 证券简称：泰坦科技 公告编号：2025-028 上海泰坦科技股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 截至 2025 年 5 月 30 日，上海泰坦科技股份有限公司（以下简称"公司" "泰坦科技"）已提前将于 2025 年 6 月 13 日到期的前次用于暂时补充流动资金 的 15,000 万元提前全部归还至募集资金专用账户，并将上述募集资金的归还情况 通知了公司的保荐机构及保荐代表人； 2025 年 6 月 27 日，公司召开了第四届董事会第十六次会议、第四届监 事会第十五次会议，审议通过了《关于使用部分闲置募集资金暂时补充流动资金 的议案》。根据募集资金投资项目的资金使用计划及项目的建设进度，在确保不 影响募集资金投资项目建设进度的前提下，为提高募集资金使用效率，减少公司 财务费用，降低公司运营成本，公司拟使用额度不超过人民币 15,000.00 万元 （含本数）的闲置的 2021 年度向特定对象发行 A 股股票募 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-027 第四届监事会第十五次会议决议公告 上海泰坦科技股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况： 上海泰坦科技股份有限公司（以下简称"公司"）第四届监事会第十五次会 议通知已于 2025 年 6 月 18 日以书面方式送达全体监事，会议于 2025 年 6 月 27 日在上海市徐汇区石龙路 89 号会议室召开，本次会议由监事会主席顾梁先生召 集并主持，应到监事 3 人，实到监事 3 人。本次会议的召集和召开符合《中华人 民共和国公司法》（以下简称"《公司法》"）和《上海泰坦科技股份有限公司 章程》（以下简称"《公司章程》"）等相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况： 与会监事就如下议案进行了审议，并表决通过以下事项： 1、审议通过《关于使用部分闲置募集资金暂时补充流动资金的议案》 具体内容详见同日刊载于上海证券交易所网站（www.sse.com.cn）的公司《关 于使用部分闲置募集资金暂时补充流 ...

Core Viewpoint - Titan Technology has established a smart production base in Yichang, Hubei, which represents a significant shift in China's scientific service industry, moving from reliance on imported reagents and equipment to a strong domestic presence [1][2]. Company Development - Titan Technology was founded by a group of university students aiming to provide better services for laboratories, focusing on the reliability of reagents and equipment [2][3]. - The company received initial funding of 200,000 yuan from the Shanghai University Student Science and Technology Entrepreneurship Fund, which has supported numerous entrepreneurial projects since its inception in 2006 [2]. Business Strategy - The company has shifted its strategy from merely pursuing scale to focusing on profitability, with a significant increase in the sales and gross margin of its proprietary brands [4][5]. - In 2024, the sales revenue from proprietary brands accounted for 63.23% of total sales, with a gross margin of 84.74%, indicating a strong competitive position in the market [4]. Mergers and Acquisitions - Titan Technology has actively pursued mergers and acquisitions to expand its proprietary brand portfolio, completing acquisitions of three companies and establishing two joint ventures in 2024 [5][6]. - The acquisition of Anhui Tiandi High-Purity Solvent Co., Ltd. significantly increased its production capacity from 3,800 tons to 13,800 tons after modernization [5]. Product Development - The company has launched new high-end scientific instruments, such as the IVScope8000Pro small animal imaging system, and developed gold standard chromatographic solvents, which have received positive market feedback [6][7]. - The gold standard chromatographic solvents have been upgraded to significantly reduce impurities, meeting or exceeding the standards of imported brands [6]. Digital Transformation - Titan Technology emphasizes digitalization and modeling in its operations to enhance efficiency and reduce costs, including the development of an intelligent warehousing and logistics system [7][8]. - The company has implemented a full inventory QR code digital management system, improving inventory management efficiency and traceability [7]. Future Outlook - The smart production base is designed to operate with minimal human intervention, utilizing advanced AI algorithms for real-time data analysis and predictive maintenance, which will enhance product quality and operational efficiency [8].

Core Insights - The 2024 revenue of the domestic instrument industry shows significant differentiation, with leading companies like Antu Bio achieving counter-cyclical growth while others face challenges due to market contraction and cost pressures [2][4] Group 1: Revenue and Income Disparities - The income of executives in the instrument sector has widened significantly compared to last year, primarily driven by high dividends [4] - Antu Bio's chairman, Miao Yongjun, is the only executive with an income exceeding 100 million yuan, with 99% of his income coming from dividends [4] - The dividend payout ratio for Antu Bio is 60.28% of net profit, while Tailin Bio has an even higher ratio of 91.94%, raising concerns about sustainable development [4] Group 2: Growth Drivers and Market Challenges - The biopharmaceutical supply chain and overseas markets are identified as core growth drivers, with Antu Bio's overseas revenue increasing by 36.25% year-on-year and Wanyi Technology achieving a remarkable 447% growth [4] - Traditional sectors like environmental monitoring and industrial process analysis are under severe pressure, as evidenced by the declining income of Xuedilong's chairman, which fell from 140 million yuan in 2022 to 110 million yuan in 2023 [5] Group 3: Cost Pressures and Profitability - Cost pressures are intensifying, squeezing net profit margins across the industry, with Tailin Bio facing significant profit margin erosion due to raw material price increases and price wars [6] - Despite a 15.01% year-on-year revenue growth, Lihua Technology experienced a decline in net profit due to rising costs and increased expenses [6] - Companies like Nanwei Technology have successfully implemented quality improvement and efficiency enhancement measures, restoring growth in core business areas while controlling expenses [6] Group 4: Executive Compensation Trends - The average pre-tax salary of executives has decreased to approximately 860,000 yuan, down from 1.2 million yuan last year, reflecting cost-cutting measures amid profit pressures [9] - The compensation structure for executives in the instrument industry is evolving, emphasizing the importance of strategic transformation, industry upgrades, and cost management [9]

Core Viewpoint - The article provides a comprehensive analysis of the revenue and profit per employee of 52 listed instrument companies in China for the year 2024, highlighting the disparities in operational efficiency and management capabilities within the industry [1][2]. Revenue Per Employee Ranking - The top company, Mindray Medical, achieved a revenue per employee of 1.94 million yuan, with total revenue of 36.73 billion yuan and 21,667 employees [4][7]. - Titan Technology and Meiya Optoelectronics follow with revenue per employee of 1.66 million yuan and 1.65 million yuan, respectively, indicating strong operational performance in their respective fields [4][7]. - A total of 10 companies reported revenue per employee exceeding 1 million yuan, showcasing their leading positions in technology innovation and market expansion [7]. - The overall average revenue per employee for the 52 companies is 770,000 yuan, suggesting significant room for improvement across the industry [7]. Profit Per Employee Ranking - Mindray Medical also leads in profit per employee with 620,000 yuan, reflecting its strong brand and diversified product matrix [10][13]. - Meiya Optoelectronics ranks second with a profit per employee of 460,000 yuan, demonstrating effective cost control and profitability [12][13]. - Notably, 9 companies reported negative profit per employee, indicating challenges in maintaining profitability amidst competitive pressures [13][14]. - The overall data reveals that only 3 companies have a profit per employee exceeding 300,000 yuan, highlighting the profitability challenges faced by the majority of listed instrument companies [14]. Industry Insights - The analysis indicates that many companies struggle with low revenue and profit per employee, emphasizing the need for enhanced operational efficiency and management practices [16]. - Companies are encouraged to invest in talent development, optimize product structures, and enhance research and development efforts to improve competitiveness [16]. - The article suggests that government and industry associations should play a role in fostering innovation and creating a fair competitive environment to support the growth of the instrument industry [16].

Core Points - The company announced a cash dividend of RMB 0.07 per share, totaling RMB 11,510,588.39 for all shareholders [1] - The profit distribution plan was approved at the annual shareholders' meeting on May 20, 2025 [1] - The dividend will be distributed based on the total share capital of 164,436,977 shares [1] Distribution Details - The cash dividend will be distributed to shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [1] - The actual cash dividend after tax for individual shareholders holding shares for less than one year is RMB 0.07 per share, while those holding for over one year are exempt from personal income tax [2] - For Qualified Foreign Institutional Investors (QFII), the after-tax cash dividend is RMB 0.063 per share due to a 10% withholding tax [3][4] Taxation Information - Individual shareholders holding shares for less than one month will incur a 20% tax on dividends, while those holding between one month and one year will incur a 10% tax [2] - Other corporate shareholders are responsible for their own tax declarations, with a pre-tax dividend of RMB 0.07 per share [4]